| Literature DB >> 29229635 |
Denis Malvy1, Marylin Torrentino-Madamet2,3,4, Coralie L'Ollivier5,6, Marie-Catherine Receveur1, Fakhri Jeddi5,6, Laurence Delhaes7, Renaud Piarroux5,6, Pascal Millet7, Bruno Pradines8,3,4.
Abstract
We report evidence, confirmed by the lack of travel activity outside of France and genetic diversity analysis using polymorphic microsatellite markers, that Plasmodium falciparum malaria infection effectively treated with an artemisinin-based combination can remain dormant and relapse during pregnancy at least 2 years after treatment.Entities:
Keywords: Plasmodium falciparum; antimalarial drug; in vitro; in vivo; malaria; molecular marker; resistance
Mesh:
Substances:
Year: 2018 PMID: 29229635 PMCID: PMC5786779 DOI: 10.1128/AAC.01892-17
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191